Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases

Patent metadata

Field	Value
Publication number	US-9499549-B2
Application number	US-201314434021-A
Country	US
Kind code	B2
Filing date	Oct 9, 2013
Priority date	Oct 10, 2012
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases.

First claim

The invention claimed is:

1. A compound of formula (I)

a pharmaceutically acceptable salt or solvate thereof wherein;
R 1 is H, fluorine or methyl;
R 2 is H, halogen or C 1-3 alkyl;
R 3 is C 1-6 alkyl optionally substituted by aryl wherein said aryl is optionally-substituted by one or more substituents independently selected from the group consisting of aryloxy, halogen, aryl, alkylamino, dialkylamino, C 1-6 alkyl, —CO 2 H, —C(O)OC 1-6 alkyl, —CONH 2 , —CN, and C 1-6 alkoxy; or
R 3 is C 1-6 alkyl optionally substituted by C 1-6 alkene, C 3-7 cycloalkyl or C 3-7 heterocycloalkyl; or
R 3 is C 1-6 alkyl optionally substituted by C 1-6 alkoxy wherein said C 1-6 alkoxy is optionally substituted by aryl; and
R 4 is C 1-8 alkyl optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, C 1-6 alkoxy, C 1-6 alkyl, C 3-7 cycloalkyl, C 2-6 alkenyl, aryl, heteroaryl, and C 3-7 cycloalkyl wherein said heteroaryl and said C 3-7 cycloalkyl are optionally substituted by C 1-6 alkyl;
with the proviso that 2-amino, 4-(N-butylamino)-5-(alphamethylbenzyl)pyrrolo[3,2-d] pyrimidine is excluded.

2. A compound as claimed in claim 1 , wherein R 3 is methyl optionally substituted by aryl.

3. A compound as claimed in claim 1 , wherein each of R 3 and R 4 is independently C 1-3 alkyl substituted by aryl.

4. A compound as claimed in claim 1 , wherein R 1 is fluorine and R 2 is hydrogen.

5. A pharmaceutical composition comprising a compound as claimed in claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

6. A compound as claimed in claim 1 , wherein R 3 is aryl-substituted C 1-3 alkyl and the aryl in said aryl-substituted C 1-3 alkyl is optionally substituted by one or more substituents independently selected from the group consisting of aryloxy, halogen, aryl, alkylamino, dialkylamino, C 1-6 alkyl, —CO 2 H, C(O)OC 1-6 alkyl, —CONH 2 , —CN, and C 1-6 alkoxy; and R 4 is aryl-substituted C 1-3 alkyl.

Assignees

• Janssen Sciences Ireland Uc

Inventors

• Mcgowan David Craig
• Last Stefaan Julien
• Pieters Serge Maria Aloysius
• EMBRECHTS Werner
• Jonckers Tim Hugo Maria
• Raboisson Pierre Jean-Marie Bernard

Classifications

• A61P31/12

  Antivirals · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/407

  condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title